Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marisa Palmeri
Observed names:
M. Palmeri,
Palmeri, Marisa
Institutions:
Rutgers, The State University of New Jersey,
Rutgers Cancer Institute
Observed institutions:
Rutgers, The State University of New Jersey,
Rutgers Cancer Institute,
Rutgers New Jersey Medical School
OpenAlex ID:
A5103959629
Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma
2021
·
J. Randall Patrinely
, Rebecca Johnson
, et al.
·
JAMA Oncology
·
254
PDF
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors
2021
·
J. Randall Patrinely
, Ben McGuigan
, et al.
·
OncoImmunology
·
65
Cutaneous angiosarcoma: A review of current evidence for treatment with checkpoint inhibitors
2023
·
Lucy Guan
, Marisa Palmeri
, et al.
·
Frontiers in Medicine
·
25
PDF
Characterization of Research Mentorship During Medical School for Future Radiation Oncology Trainees
2024
·
Marisa Palmeri
, Kristy Bono
, et al.
·
Advances in Radiation Oncology
·
1
PDF
Nivolumab with doxorubicin, vinblastine, and dacarbazine in older adults with classic Hodgkin lymphoma: do S1826 results hold up in the real world?
2026
·
Xu, Yizhe
, Niu, Alex
, et al.
·
UNC Libraries
Nivolumab with doxorubicin, vinblastine, and dacarbazine in older adults with classic Hodgkin lymphoma: do S1826 results hold up in the real world?
2026
·
Pallawi Torka
, Allison M. Bock
, et al.
·
Haematologica
PDF
Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real‐world analysis from 20 US centers
2026
·
Allison M. Bock
, Peirong Hao
, et al.
·
HemaSphere
A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study
2025
·
Allison Bock
, Efrat Luttwak
, et al.
·
Blood
PDF
Nivolumab with doxorubicin, vinblastine, and dacarbazine (NAVD) in older adults with classic Hodgkin lymphoma: Do S1826 results hold up in the real world?
2025
·
Pallawi Torka
, Allison Bock
, et al.
·
Blood
PDF
Effect of biopsy requirement on patient enrollment to phase I trials in cancer.
2025
·
Marisa Palmeri
, Mohammad Ghalib
, et al.
·
Journal of Clinical Oncology
Assessment of Research Mentorship During Medical School for Future Radiation Oncology Trainees
2023
·
Marisa Palmeri
, Kristy Bono
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
Assessment of Medical Student Research Mentorship Based on Publications in ASTRO Journals
2022
·
K. Bono
, M. Palmeri
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
A Novel Method to Characterize Medical School Research Productivity among Radiation Oncology Residents
2022
·
Austin Huang
, Elizabeth Pan
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
194 A multicenter characterization of chronic toxicities following adjuvant anti-PD-1 therapy for high risk resected melanoma
2020
·
James Patrinely
, Rebecca Johnson
, et al.
·
Regular and Young Investigator Award Abstracts
Show more works
View as search
Works count:
14
Citation count:
345
H-index:
3
I10-index:
3
Year
Topic
Type